Cite
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
MLA
Tada, Toshifumi, et al. “Outcomes of Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 IMbrave150 Trial.” Alimentary Pharmacology & Therapeutics, vol. 60, no. 2, July 2024, pp. 233–45. EBSCOhost, https://doi.org/10.1111/apt.18037.
APA
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Nishikawa, H., Tsuji, K., Ishikawa, T., Tajiri, K., Koshiyama, Y., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., … Kudo, M. (2024). Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. Alimentary Pharmacology & Therapeutics, 60(2), 233–245. https://doi.org/10.1111/apt.18037
Chicago
Tada, Toshifumi, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, et al. 2024. “Outcomes of Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 IMbrave150 Trial.” Alimentary Pharmacology & Therapeutics 60 (2): 233–45. doi:10.1111/apt.18037.